Peter Chase, MD
Professor Emeritus, Pediatrics

Clinic (303) 724-2323
Print Profile
Email Profile
Featured Provider Photo

Gender: Male
Languages: English
Department, Section/Division: Pediatrics

Practice Locations

Hospital Affiliation
  • Children's Hospital Colorado
Center Affiliations

Specialty Information

Specialties
  • Pediatrics - Pediatric Endocrinology, Board Certification
Conditions & Treatments
  • Child and Teen Health
  • Juvenile Diabetes

Education & Training

Medical Schools:
  • MD, University of Wisconsin School of Medicine and Public Health (1961)

Undergraduate Schools:
  • BS, University of Wisconsin System (WI) (1958)

Residency Program:
  • Stanford University Program, Pediatrics (1964)

Fellowships:
  • National Institutes of Health Clinical Center Program, Pediatrics (1967)
  • Stanford University Program, Pediatrics (1965)

Recognition & Awards

  • Lifetime Achievement Award, Juvenile Diabetes Research Foundation (2003)
  • Outstanding Physician Clinician in Diabetes, American Diabetes Association (2001)

Professional Memberships

  • American Diabetes Association, Member
  • American Pediatric Society (APS), Member
  • Federation of American Societies for Experimental Biology, Member
  • Society For Pediatric Research (SPR), Member
  • The American Society for Clinical Nutrition, Member
  • Western Society for Pediatric Research (WSPR), Member

Research & Grants

Research interests for Patients:
Clinical trials of agents for the prevention of type I diabetes, including cyclosporine, nicotinamide, BCG and the subcutaneous and intravenous administration of insulin. He is currently one of nine center directors for the Diabetes Prevention Trial (DPT-1). Continuous glucose monitoring (CGM) in children has been a recent area of emphasis. The use of CGM to prevent severe hypoglycemia and to improve HbA1c levels is currently being studied

Information for Referring Providers

Clinical Interests for Referring Providers
Pediatric Diabetes

Research Interest for Referring Providers
Clinical trials of agents for the prevention of type I diabetes, including cyclosporine, nicotinamide, BCG and the subcutaneous and intravenous administration of insulin. He is currently one of nine center directors for the Diabetes Prevention Trial (DPT-1). Development of strategies aimed at prevention of the eye and kidney complications of type I diabetes, based upon controlling HbA1c levels and blood pressure levels. His first longitudinal report of HbA1c levels in relation to diabetic eye and kidney complications was reported in JAMA in 1989. The development of new insulins and their use in children: he was the first to report the use of postprandial Humalog in toddlers and on the use of Humalog in the phone management of ketonuria. Ketoacidosis has been of interest for many years (Pediatrics in Review, 1990). A report is now in progress relating to the prevention of severe DKA and cerebral edema. Continuous glucose monitoring (CGM) in children has been a recent area of emphasis. The use of CGM to prevent severe hypoglycemia and to improve HbA1c levels is currently being studied
Clinic Phone: (303) 724-2323
Fax Phone: (303) 724-6784